Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

David Wyles

Concepts (254)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antiviral Agents
60
2026
769
11.160
 Why?
Hepatitis C, Chronic
32
2025
153
8.910
 Why?
Hepacivirus
49
2026
242
8.280
 Why?
Hepatitis C
30
2026
256
8.050
 Why?
Benzimidazoles
19
2026
189
4.350
 Why?
Drug Resistance, Viral
18
2025
126
3.820
 Why?
Coinfection
15
2020
143
2.820
 Why?
HIV Infections
28
2022
3195
2.700
 Why?
Quinoxalines
8
2026
65
2.360
 Why?
Ribavirin
15
2020
81
2.260
 Why?
Sulfonamides
14
2026
583
2.250
 Why?
Sofosbuvir
16
2022
61
2.160
 Why?
Fluorenes
7
2020
45
2.110
 Why?
Viral Nonstructural Proteins
10
2025
63
2.060
 Why?
Liver Cirrhosis
8
2020
288
2.060
 Why?
Drug Therapy, Combination
26
2020
1043
1.730
 Why?
Uridine Monophosphate
5
2016
16
1.600
 Why?
Carbamates
9
2020
50
1.370
 Why?
Anti-Retroviral Agents
5
2019
251
1.350
 Why?
Protease Inhibitors
10
2020
102
1.320
 Why?
Pyrrolidines
10
2026
125
1.310
 Why?
Hepatitis B, Chronic
3
2019
22
1.270
 Why?
Proline
12
2026
82
1.250
 Why?
Genotype
21
2025
1857
1.140
 Why?
Sustained Virologic Response
12
2026
46
1.130
 Why?
Congresses as Topic
3
2021
224
1.110
 Why?
Hepatitis, Viral, Human
3
2021
21
1.090
 Why?
Cyclopropanes
12
2026
84
0.980
 Why?
Lactams, Macrocyclic
11
2026
51
0.910
 Why?
Drug Users
2
2024
43
0.910
 Why?
Heterocyclic Compounds, 4 or More Rings
3
2017
23
0.760
 Why?
HIV-1
8
2020
908
0.730
 Why?
Respiratory Insufficiency
1
2026
327
0.720
 Why?
Treatment Failure
6
2025
360
0.710
 Why?
Virus Replication
7
2012
521
0.700
 Why?
Pyridines
1
2026
609
0.690
 Why?
RNA, Viral
10
2026
693
0.660
 Why?
Disease Eradication
1
2020
8
0.660
 Why?
Humans
80
2026
145783
0.650
 Why?
Organophosphonates
4
2011
95
0.640
 Why?
Homosexuality, Male
2
2021
231
0.610
 Why?
Valine
7
2020
83
0.600
 Why?
Anti-HIV Agents
6
2020
912
0.570
 Why?
Treatment Outcome
20
2026
11794
0.550
 Why?
Aminoisobutyric Acids
6
2026
9
0.550
 Why?
Middle Aged
34
2026
36309
0.540
 Why?
Nucleic Acid Synthesis Inhibitors
2
2015
16
0.520
 Why?
Leucine
6
2026
116
0.520
 Why?
Ritonavir
6
2020
75
0.510
 Why?
Imidazoles
2
2015
247
0.510
 Why?
Darunavir
1
2017
20
0.500
 Why?
Male
43
2026
73011
0.490
 Why?
Uracil
5
2020
36
0.480
 Why?
Adult
33
2026
40881
0.480
 Why?
Antiretroviral Therapy, Highly Active
3
2015
279
0.460
 Why?
Anilides
5
2020
84
0.460
 Why?
Education, Medical, Continuing
1
2016
134
0.440
 Why?
Female
41
2026
79045
0.440
 Why?
Biomedical Research
1
2021
719
0.420
 Why?
Oligopeptides
2
2013
267
0.410
 Why?
Pyridazines
1
2014
57
0.410
 Why?
Adenine
4
2020
339
0.400
 Why?
2-Naphthylamine
5
2020
6
0.400
 Why?
Viral Load
7
2020
526
0.400
 Why?
Macrocyclic Compounds
3
2019
15
0.390
 Why?
Purines
1
2014
187
0.380
 Why?
Quinolines
1
2014
190
0.370
 Why?
Aged
18
2026
26217
0.370
 Why?
Replicon
3
2009
12
0.370
 Why?
Liver
1
2021
1899
0.360
 Why?
Scavenger Receptors, Class B
1
2012
14
0.360
 Why?
Disease Management
1
2016
653
0.360
 Why?
Mass Screening
4
2025
1361
0.320
 Why?
Retreatment
2
2021
80
0.320
 Why?
Drug Synergism
3
2008
354
0.310
 Why?
Acquired Immunodeficiency Syndrome
2
2020
237
0.280
 Why?
Dideoxynucleosides
2
2005
24
0.280
 Why?
Liver Diseases
2
2016
305
0.270
 Why?
Interferon-alpha
4
2013
193
0.270
 Why?
Nucleoside-Triphosphatase
3
2017
13
0.270
 Why?
Cytokines
1
2015
2069
0.260
 Why?
DEAD-box RNA Helicases
3
2017
84
0.250
 Why?
Serine Endopeptidases
3
2017
129
0.250
 Why?
Amino Acid Substitution
2
2018
302
0.250
 Why?
Cytosine
2
2009
49
0.240
 Why?
Indolizines
1
2026
13
0.240
 Why?
Global Health
2
2020
403
0.240
 Why?
Hospitalization
3
2026
2461
0.230
 Why?
Multiplex Polymerase Chain Reaction
1
2026
56
0.230
 Why?
Hepatitis B virus
2
2019
33
0.220
 Why?
HIV
2
2019
251
0.210
 Why?
Hepatitis
1
2004
43
0.210
 Why?
Double-Blind Method
3
2026
2064
0.210
 Why?
Herpes Simplex
1
2005
99
0.210
 Why?
Alanine
2
2021
169
0.200
 Why?
Interferons
2
2015
186
0.190
 Why?
Prevalence
3
2019
2875
0.190
 Why?
Mutation, Missense
3
2014
335
0.180
 Why?
Hospitals
2
2024
733
0.180
 Why?
Pyrazoles
1
2026
517
0.180
 Why?
Respiratory Tract Infections
1
2026
396
0.180
 Why?
Interferon beta-1a
1
2021
14
0.170
 Why?
Young Adult
10
2019
14254
0.170
 Why?
Phylogeny
1
2025
917
0.170
 Why?
Hepatitis A
1
2021
25
0.170
 Why?
Adenosine Monophosphate
1
2021
85
0.160
 Why?
Feasibility Studies
1
2025
1115
0.160
 Why?
Hepatitis B
1
2021
66
0.160
 Why?
Tenofovir
2
2020
301
0.160
 Why?
World Health Organization
1
2020
104
0.160
 Why?
Benzopyrans
2
2017
30
0.160
 Why?
Disease Progression
2
2019
2865
0.150
 Why?
Data Interpretation, Statistical
2
2018
368
0.150
 Why?
Polyethylene Glycols
2
2015
649
0.150
 Why?
Drug Combinations
4
2026
396
0.150
 Why?
Esters
2
2009
71
0.140
 Why?
CD4 Lymphocyte Count
2
2017
280
0.140
 Why?
Ribosomes
2
2010
193
0.140
 Why?
United States
10
2025
16126
0.140
 Why?
Immunologic Factors
1
2020
260
0.130
 Why?
Emergency Service, Hospital
3
2025
2383
0.130
 Why?
Nucleic Acid Conformation
4
2014
724
0.130
 Why?
Alanine Transaminase
1
2018
151
0.130
 Why?
DNA, Viral
1
2019
356
0.130
 Why?
Genes, Viral
1
2016
88
0.120
 Why?
DNA Mutational Analysis
1
2018
410
0.120
 Why?
High-Throughput Nucleotide Sequencing
2
2016
534
0.120
 Why?
Molecular Structure
2
2008
487
0.120
 Why?
Mutation
2
2018
4090
0.120
 Why?
Patient Compliance
1
2020
588
0.120
 Why?
Survival Analysis
1
2019
1378
0.110
 Why?
Dose-Response Relationship, Drug
2
2017
2028
0.110
 Why?
Adolescent
5
2022
22577
0.110
 Why?
Regulatory Sequences, Ribonucleic Acid
1
2014
18
0.110
 Why?
AIDS-Related Opportunistic Infections
1
2015
130
0.110
 Why?
Chemokines
1
2015
217
0.110
 Why?
Chemokine CXCL10
1
2014
39
0.100
 Why?
Drug Interactions
1
2015
405
0.100
 Why?
Risk Assessment
2
2025
3752
0.100
 Why?
Opiate Substitution Treatment
1
2016
189
0.100
 Why?
Phenylenediamines
1
2013
14
0.100
 Why?
Fibrosis
1
2016
561
0.100
 Why?
Viral Proteins
2
2014
350
0.100
 Why?
Prospective Studies
5
2025
8078
0.100
 Why?
Microbial Sensitivity Tests
2
2012
365
0.090
 Why?
Prognosis
2
2019
4330
0.090
 Why?
Equivalence Trials as Topic
2
2023
35
0.090
 Why?
Quality of Life
1
2025
3211
0.090
 Why?
Drug Discovery
1
2013
153
0.090
 Why?
Administration, Oral
1
2014
867
0.090
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
261
0.080
 Why?
Case-Control Studies
2
2017
3634
0.080
 Why?
Cohort Studies
5
2024
6033
0.080
 Why?
Models, Molecular
3
2012
1599
0.080
 Why?
Mental Disorders
1
2020
1171
0.080
 Why?
Prodrugs
1
2011
52
0.080
 Why?
Nucleosides
1
2010
25
0.080
 Why?
Riboswitch
1
2012
64
0.080
 Why?
Telemedicine
1
2020
967
0.080
 Why?
Japan
2
2021
149
0.080
 Why?
Drug Administration Schedule
3
2017
782
0.080
 Why?
Cell Line, Tumor
2
2008
3551
0.070
 Why?
Drug Design
1
2010
175
0.070
 Why?
Cell Line
2
2012
2823
0.070
 Why?
Biomarkers
1
2020
4302
0.070
 Why?
Randomized Controlled Trials as Topic
3
2023
1752
0.070
 Why?
Piperidines
1
2010
222
0.070
 Why?
Phenylthiourea
1
2008
5
0.070
 Why?
Practice Guidelines as Topic
1
2016
1582
0.070
 Why?
Immunity, Innate
1
2014
835
0.070
 Why?
Body Mass Index
1
2017
2447
0.070
 Why?
Plasmids
1
2009
373
0.070
 Why?
Structure-Activity Relationship
1
2009
563
0.070
 Why?
Inhibitory Concentration 50
1
2006
91
0.060
 Why?
Luciferases
1
2006
154
0.060
 Why?
Genes, Reporter
1
2006
277
0.060
 Why?
Retrospective Studies
6
2026
17330
0.060
 Why?
Thailand
1
2025
19
0.060
 Why?
Saquinavir
1
2004
1
0.050
 Why?
Simplexvirus
1
2005
82
0.050
 Why?
Drug Labeling
1
2005
37
0.050
 Why?
Indinavir
1
2004
7
0.050
 Why?
Nelfinavir
1
2004
8
0.050
 Why?
Uganda
1
2025
90
0.050
 Why?
Nevirapine
1
2004
18
0.050
 Why?
Benzoxazines
1
2004
31
0.050
 Why?
Pandemics
2
2024
1711
0.050
 Why?
Oxazines
1
2004
37
0.050
 Why?
Lopinavir
1
2004
30
0.050
 Why?
Brazil
1
2025
179
0.050
 Why?
Zidovudine
1
2004
77
0.050
 Why?
Liver Function Tests
1
2004
105
0.050
 Why?
Alkynes
1
2004
67
0.050
 Why?
Transfection
1
2006
927
0.050
 Why?
Reverse Transcriptase Inhibitors
1
2004
87
0.050
 Why?
Time Factors
1
2015
7134
0.050
 Why?
Bone Marrow Transplantation
1
2005
298
0.050
 Why?
Pregnancy
1
2017
7216
0.050
 Why?
Pyrimidinones
1
2004
125
0.050
 Why?
Recombinant Fusion Proteins
1
2006
666
0.050
 Why?
South Africa
1
2025
266
0.050
 Why?
Carcinoma, Hepatocellular
1
2006
373
0.050
 Why?
Polyphosphates
1
2022
43
0.040
 Why?
Singapore
1
2021
27
0.040
 Why?
Republic of Korea
1
2021
43
0.040
 Why?
Pragmatic Clinical Trials as Topic
1
2022
133
0.040
 Why?
Dried Blood Spot Testing
1
2022
126
0.040
 Why?
Mexico
1
2021
233
0.040
 Why?
Protein Biosynthesis
2
2014
452
0.040
 Why?
Multicenter Studies as Topic
1
2022
413
0.040
 Why?
Liver Neoplasms
1
2006
777
0.040
 Why?
Raltegravir Potassium
1
2019
18
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
75
0.040
 Why?
Clinical Trials, Phase III as Topic
1
2019
116
0.040
 Why?
Intensive Care Units
1
2024
924
0.030
 Why?
Drug Resistance, Multiple, Viral
1
2017
10
0.030
 Why?
Kinetics
1
2020
1568
0.030
 Why?
Longitudinal Studies
1
2024
2968
0.030
 Why?
Oxygen
1
2021
981
0.030
 Why?
Medicaid
1
2020
467
0.030
 Why?
Program Evaluation
1
2020
944
0.030
 Why?
RNA
1
2022
912
0.030
 Why?
Incidence
2
2013
2934
0.030
 Why?
Cell-Free System
1
2014
53
0.030
 Why?
Hepatitis C Antibodies
1
2014
11
0.030
 Why?
Spain
1
2014
50
0.030
 Why?
Polymorphism, Genetic
1
2017
615
0.030
 Why?
Enzyme-Linked Immunosorbent Assay
1
2016
849
0.030
 Why?
Withholding Treatment
1
2013
80
0.020
 Why?
Patient Acceptance of Health Care
1
2020
883
0.020
 Why?
Patient Care
1
2014
120
0.020
 Why?
Early Diagnosis
1
2014
251
0.020
 Why?
Risk Factors
2
2020
10919
0.020
 Why?
Aged, 80 and over
2
2019
8347
0.020
 Why?
Patient Reported Outcome Measures
1
2017
498
0.020
 Why?
Plasma
1
2014
223
0.020
 Why?
Fluorescence Resonance Energy Transfer
1
2012
179
0.020
 Why?
Virus Internalization
1
2010
65
0.020
 Why?
Ligands
1
2012
668
0.020
 Why?
Recombinant Proteins
1
2013
1368
0.020
 Why?
Magnesium
1
2009
157
0.020
 Why?
Pilot Projects
1
2015
1898
0.020
 Why?
Lamivudine
1
2009
65
0.020
 Why?
Genome, Viral
1
2009
214
0.020
 Why?
Logistic Models
1
2013
2139
0.020
 Why?
Referral and Consultation
1
2014
869
0.020
 Why?
Phenotype
1
2014
3170
0.010
 Why?
Base Sequence
1
2009
2171
0.010
 Why?
Severity of Illness Index
1
2013
2933
0.010
 Why?
Mice, Transgenic
1
2009
2191
0.010
 Why?
Animals
2
2018
38102
0.010
 Why?
Substance-Related Disorders
1
2011
1103
0.010
 Why?
Signal Transduction
1
2009
5224
0.010
 Why?
Mice
1
2009
18356
0.010
 Why?
Wyles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (254) concept(s)
_
Co-Authors Expand Description
See all (20) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)